Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Invested Capital (2016 - 2025)

Northwest Biotherapeutics' Invested Capital history spans 16 years, with the latest figure at -$50.9 million for Q4 2025.

  • Quarterly results put Invested Capital at -$50.9 million for Q4 2025, up 44.87% from a year ago — trailing twelve months through Dec 2025 was -$50.9 million (up 44.87% YoY), and the annual figure for FY2025 was -$50.9 million, up 44.87%.
  • Invested Capital for Q4 2025 was -$50.9 million at Northwest Biotherapeutics, up from -$99.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of -$11.3 million in Q1 2021 to a low of -$100.8 million in Q3 2022.
  • The 5-year median for Invested Capital is -$60.6 million (2023), against an average of -$57.3 million.
  • The sharpest move saw Invested Capital skyrocketed 77.43% in 2021, then tumbled 426.84% in 2022.
  • Year by year, Invested Capital stood at -$17.2 million in 2021, then crashed by 176.31% to -$47.5 million in 2022, then tumbled by 36.36% to -$64.8 million in 2023, then tumbled by 42.33% to -$92.3 million in 2024, then soared by 44.87% to -$50.9 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at -$50.9 million, -$99.0 million, and -$99.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.